株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Opexa Therapeutics, Inc. の製品パイプライン分析

Opexa Therapeutics, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321993
出版日 ページ情報 英文 24 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
Opexa Therapeutics, Inc. の製品パイプライン分析 Opexa Therapeutics, Inc. - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 24 Pages
概要

Opexa Therapeutics, Inc. は米国に本社を置くバイオテクノロジー企業で、硬化症や関節リウマチ、糖尿病、心不全などの疾患治療用に自己細胞医薬品の開発を行っています。単球由来幹細胞を生産するための技術を開発しました。

当レポートでは、Opexa Therapeutics, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Opexa Therapeutics, Inc. の基本情報

  • Opexa Therapeutics, Inc. の概要
  • 主要情報
  • 企業情報

Opexa Therapeutics, Inc. :R&Dの概要

  • 主な治療範囲

Opexa Therapeutics, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Opexa Therapeutics, Inc. :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Opexa Therapeutics, Inc. :薬剤プロファイル

  • imilecleucel-t
  • OPX-212
  • Stem Cell Therapy for Type 1 Diabetes

Opexa Therapeutics, Inc. :パイプライン分析

  • 投与経路別
  • 分子タイプ別

Opexa Therapeutics, Inc. :最新のパイプライン情報

Opexa Therapeutics, Inc. :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07544CDB

Summary

Global Markets Direct's, 'Opexa Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Opexa Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Opexa Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Opexa Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Opexa Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Opexa Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Opexa Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Opexa Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Opexa Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Opexa Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Opexa Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Opexa Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Opexa Therapeutics, Inc. Snapshot
    • Opexa Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Opexa Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Opexa Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Opexa Therapeutics, Inc. - Pipeline Products Glance
    • Opexa Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Opexa Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Opexa Therapeutics, Inc. - Drug Profiles
    • imilecleucel-t
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPX-212
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Type 1 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Opexa Therapeutics, Inc. - Pipeline Analysis
    • Opexa Therapeutics, Inc. - Pipeline Products by Target
    • Opexa Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Opexa Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Opexa Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Opexa Therapeutics, Inc. - Recent Pipeline Updates
  • Opexa Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Opexa Therapeutics, Inc., Key Information
  • Opexa Therapeutics, Inc., Key Facts
  • Opexa Therapeutics, Inc. - Pipeline by Indication, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Opexa Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Opexa Therapeutics, Inc. - Phase II, 2015
  • Opexa Therapeutics, Inc. - Preclinical, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Target, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Opexa Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Opexa Therapeutics, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Opexa Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Opexa Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Opexa Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top